Clinical trial • Phase I • Oncology|Haematology
EXS73565 for Chronic lymphocytic leukemia|Richter's transformation|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Follicular lymphoma|Marginal zone lymphoma
Phase I trial of EXS73565 for Chronic lymphocytic leukemia|Richter's transformation|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Follicular lymphoma…
Overview
- Trial Therapeutic Area
- Oncology|Haematology
- Trial Disease
- Chronic lymphocytic leukemia|Richter's transformation|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Follicular lymphoma|Marginal zone lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 17-10-2024
- First CTIS Authorization Date
- 23-01-2025
Trial design
adaptive Phase I trial across 15 sites in Spain, France, Greece and others.
- Adaptive
- Yes
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 85
Eligibility
Recruits 85 Vulnerable population selected; no details on consent/assent provided in the source..
- Vulnerable Population
- Vulnerable population selected; no details on consent/assent provided in the source.
Recruitment
- Planned Sample Size
- 85
- Recruitment Window Months
- 34
Geography
- Total Number Of Sites
- 15
- Total Number Of Participants
- 71
Spain
- Earliest CTIS Part Ii Submission Date
- 10-01-2025
- Latest Decision Or Authorization Date
- 23-01-2025
- Processing Time Days
- 13
- Number Of Sites
- 5
- Number Of Participants
- 15
Sites
- Site Name
- MD Anderson Cancer Center
- Department Name
- Hematology
- Contact Person Name
- Adolfo de la Fuente Burguera
- Contact Person Email
- afuente@mdanderson.es
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Hematology
- Contact Person Name
- Damian Cubillas Garcia de la Torre
- Contact Person Email
- damian.cubillas@startresearch.com
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Hematology
- Contact Person Name
- Daniel Morillo Giles
- Contact Person Email
- dmorillo@startmadrid.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Hematology
- Contact Person Name
- Miguel Angel Canales Albendea
- Contact Person Email
- eecc@unav.es
- Site Name
- Hospital Beata Maria Ana
- Department Name
- Hematology
- Contact Person Name
- Elena Gongora Otegui
- Contact Person Email
- ensayos@iobmadrid.com
France
- Earliest CTIS Part Ii Submission Date
- 24-03-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 48
- Number Of Sites
- 3
- Number Of Participants
- 20
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Service d’Hématologie
- Contact Person Name
- Benoit TESSOULIN
- Contact Person Email
- benoit.tessoulin@chu-nantes.fr
- Site Name
- Institut Bergonie
- Department Name
- Service d’Hématologie
- Contact Person Name
- Fontanet BIJOU
- Contact Person Email
- f.bijou@bordeaux.unicancer.fr
- Site Name
- Centre Hospitalier Regional De Marseille
- Department Name
- Centre d'Essais Précoces en Cancérologie de Marseille
- Contact Person Name
- Regis COSTELLO
- Contact Person Email
- regis.costello@ap-hm.fr
Greece
- Earliest CTIS Part Ii Submission Date
- 27-03-2026
- Latest Decision Or Authorization Date
- 27-04-2026
- Processing Time Days
- 31
- Number Of Sites
- 3
- Number Of Participants
- 16
Sites
- Site Name
- Geniko Nosokomeio Thessalonikis George Papanikolaou
- Department Name
- Hematology Clinic
- Contact Person Name
- Niki Stavroyianni
- Contact Person Email
- niki.stavroyianni@gmail.com
- Site Name
- General University Hospital Of Patras
- Department Name
- Hematology Department/Bone Marrow Transplantation Unit, Department of Internal Medicine
- Contact Person Name
- Alexandros Spyridonidis
- Contact Person Email
- spyridonidis@upatras.gr
- Site Name
- Laiko General Hospital Of Athens
- Department Name
- Department of Haematology and Bone Marrow Transplantation Unit
- Contact Person Name
- Theodoros Vassilakopoulos
- Contact Person Email
- theopvass@hotmail.com
Poland
- Earliest CTIS Part Ii Submission Date
- 13-02-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 91
- Number Of Sites
- 4
- Number Of Participants
- 20
Sites
- Site Name
- PRATIA MCM Kraków
- Contact Person Name
- Wojciech Jurczak
- Contact Person Email
- wojciech.jurczak@pratia.com
- Site Name
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M.Kopernika W Lodzi
- Department Name
- Oddział Hematologii Ogólnej i Chorób Wewnętrznych
- Contact Person Name
- Bartosz Puła
- Contact Person Email
- bartosz.pula@gmail.com
- Site Name
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
- Department Name
- Oddział Wieloprofilowy Zachowawczy
- Contact Person Name
- Krzysztof Giannopoulos
- Contact Person Email
- krzysztof.giannopoulos@gmail.com
- Site Name
- Aidport Sp. z o.o.
- Contact Person Name
- Michał Kwiatek
- Contact Person Email
- michal.kwiatek@aidport.pl
Sponsor
Primary sponsor
- Full Name
- Exscientia AI Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- EXS73565
Related trials
Other published trials that may interest you.
- DAUNORUBICIN HYDROCHLORIDE for Acute myeloid leukemia|Relapsed or refractory acute myeloid leukemia
- Brentuximab vedotin for Peripheral T-cell lymphoma (PTCL) | Anaplastic large cell lymphoma (ALCL) | Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | Angioimmunoblastic T-cell lymphoma (AITL) | Adult T-cell leukaemia/lymphoma (ATLL) | Enteropathy-associated T-cell lymphoma (EATL) | Hepatosplenic T-cell lymphoma | Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) | Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract | Follicular T-cell lymphoma | Nodal peripheral T-cell lymphoma with T-follicular helper phenotype
- RITUXIMAB for Diffuse large B-cell lymphoma (ABC)
- Lenalidomide for Primary central nervous system lymphoma
- Cytarabine; Daunorubicin for Myelodysplastic syndrome (higher-risk)|Oligoblastic acute myeloid leukaemia (AML)